|
1) Van Werkum JW, Heestermans AA, de Korte FI, et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis; an analysis of 431 cases. Circulation. 2009; 119: 828-34
|
|
|
|
2) Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293: 2126-30
|
|
|
|
|
|
3) Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of pre-mature discontinuation of thienopyridine therapy after drug-eluting stent placement. Results from the Premier Registry. Circulation. 2006; 113: 2803-9
|
|
|
|
|
|
4) Van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis. The Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009; 53: 1399-409
|
|
|
|
|
|
5) Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010; 362: 1374-82
|
|
|
|
|
|
6) Airoldi F, Colombo A, Morice N, et al. Incidence and predictors of drug-eluting stent thrombosis and after discontinuation of thienopyridine treatment. Circulation. 2007; 116: 745-54
|
|
|
|
|
|
7) Kimura T, Motimoto T, nakagawa Y, et al. Antiplatelet therapy and stent thrombosis after Sirolimus-eluting stent implantation. Circulation. 2009; 119: 987-95
|
|
|
|
|
|
8) McQuiad KR, Laine L. Systemic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006; 119: 624-38
|
|
|
|
|
|
9) Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systemic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50279 patients at risk of coronary artery disease. Eur Heart J. 2006; 27: 2667-74
|
|
|
|
|
|
10) OʼRiordan JM, Margey RJ, Blake G, et al. Antiplatelet agents in the perioperative period. Arch Surg. 2009; 144: 69-76
|
|
|
|
|
|
11) Oscarsson A, Gupta A, Fredrikson M, et al. To continue or discontinue aspirin in the perioperative period: a randomized controlled clinical trial. ASPIRIN trial. BJA. 2010; 104: 305-12
|
|
|
|
|
|
12) Dario Di Minno MN, Prisco D, Ruocco AL, et al. Perioperative handling of patients on antiplatelet therapy with need for surgery. Intern Emerg Med. 2009; 4: 279-88
|
|
|
|
|
|
13) Eisenberg M, Richard PR, Libersan D, et al. Safety of short-term discontinuation of anti-platelet therapy in patients with DESs. Circulation. 2009; 119: 1634-42
|
|
|
|
|
|
14) A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE) CAPRIE steering committee. Lancet. 1996; 16: 1329-39
|
|
|
|
|
|
15) Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therpy for reduction of ischemia events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting with the Triton-TIMI 38 trial. a substudy of a randomized trial. Lancet. 2008; 371: 1353- 63
|
|
|
|
|
|
16) Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndrome. N Engl J Med. 2009; 361: 1045-57
|
|
|
|
|
|
17) Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009; 360: 363-75
|
|
|
|
|
|
18) Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360: 354-62
|
|
|
|
|
|
19) OʼDonoghue ML, Braunwald E, Antman EM, et al. Pharamacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor; a analysis of two randomized trials. Lancet. 2009; 374: 989-97
|
|
|
|
|
|
20) Rassen JA, Choudhry NK, Avorn J, et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation. 2009; 120: 2322-9
|
|
|
|
|
|
21) Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors. Ann Intern Med 2010; 152: 337-45
|
|
|
|
|
|
22) Beger PB, Bhatt DL, Fuster V, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease. Results from the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial. Circulation. 2010; 121: 2575-83
|
|
|
|
|
|
23) Hochholzer W, Trenk D, Fromm M, et al. Impact of cytochrome p450 2C19 loss-of-function polymorphism and a major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol. 2010; 55: 2427-34
|
|
|
|
|
|
24) Breet NJ, van Werkman JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients under-going coronary stent implantation. JAMA. 2010; 303: 754-62
|
|
|
|
|